CareTrust's Q2 Jump Looks Great-Until You Ask What $1.5B of Buying Means for the Dividend

Q2 results were strong, but equity-funded growth is the real story

CareTrust's second quarter improved the bull case: normalized FFO per diluted weighted average share of $0.51, an increase of $0.08, or 19%, over the prior year quarter and full-year 2026 guidance both point to stronger operating momentum. But the bear case is still about funding. Management also reported $578.2 million of gross proceeds from a forward equity offering, which remain unsettled, and it sold another 2.2 million forward shares after the quarter ended. In plain English, new shareholders are helping finance the next round of acquisitions before the income payoff is fully proven.

This looks like expansion, not distress

The first thing to notice is the pace of buying. In Q2, CareTrust closed $899.6 million of investment activity closed at a blended stabilized yield of 8.9%. Year to date, that adds up to approximately $1.5 billion in investments. That is not the activity of a company pulling back under pressure.

Why the split opinion matters

Bulls can point to a balance sheet that ended the quarter at Net Debt to Annualized Normalized Run Rate EBITDA of 1.01x. Skeptics will focus on the equity story: a bigger portfolio is helpful only if it lifts per-share cash flow rather than simply spreading ownership thinner.

The balance sheet supports growth, but per-share math still matters

The key question is not whether CareTrust can keep buying. It clearly can. The harder question is whether management can turn new properties into extra distributable cash without forcing investors to choose between a weaker dividend and more dilution.

Why the timing matters now

CareTrust has already deployed approximately $1.5 billion year to date and still has a $540 million investment pipeline. If those deals close and perform as expected, the company should generate more rent streams and more earnings power. If they do not, investors may own more assets without much improvement in per-share value.

Balance-sheet strength gives management room to work

What makes the setup interesting is how little leverage shows up in the reported numbers. CareTrust reported Net Debt to Annualized Normalized Run Rate EBITDA of 1.01x and said it has about Approximately $1.4 billion as of today, including $90 million cash, $605 million under the revolving credit facility, and $671 million of unsettled equity forwards in liquidity.

That does not mean dilution is not a risk. It means management has room to keep underwriting deals without an obvious near-term refinancing crisis.

What has to stay in check

For this growth model to work, a few things need to hold:

• new lease income needs to build cash flow
• funding needs to stay available without excessive borrowing
• share growth needs to stay below income growth

So the near-term test is simple: can management turn balance-sheet room into accretive growth, not just more portfolio size?

Dilution is the main risk if yields keep falling

That is why the bear case is not about survival. It is about whether equity-funded growth is truly accretive on a per-share basis.

CareTrust already showed how that can happen. In Q2, it sold 14.4 million shares under forward equity contracts. After the quarter ended, it sold another 2.2 million shares on a forward basis. Approximately 16.6 million shares, representing $671.4 million in gross proceeds remain unsettled. Bulls can argue those shares are funding income-producing assets. Bears will argue investors already own more pieces of the company, not necessarily more value per piece.

The yield gap is the watchpoint

The other pressure point is yield erosion. In Q2, CareTrust deployed roughly $900 million at an 8.9% blended stabilized yield. Since June 30, it closed $307.9 million of investment activity closed at a blended stabilized yield of 7.8%. That gap matters because newer money may earn less than older assets.

If that trend continues, the company may have to spend more capital to fund each additional dollar of rent. In that world, bigger size alone is not enough. The stock still needs higher per-share cash flow.

What to listen for on the Aug. 7 call

The next test is whether management shifts from size to quality

Investors now have a direct opportunity to press management on a Conference Call Scheduled for Friday, August 7, 2026 at 11:00 am ET. The most useful answers will cover:

• whether new acquisitions are clearing hurdle rates that clearly exceed the cost of capital
• whether the pipeline is selective rather than driven by deployment momentum alone
• how management plans to handle unsettled forward contracts without leaning too hard on fresh dilution
• whether dividend support remains a priority even as the portfolio grows

My view is straightforward: the stock looks more attractive only if new buying increases shareholders' claim on cash flow and supports the dividend, not just portfolio size.